Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Immatics NV IMTX

Healthcare Biotechnology
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IMTX)

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

GlobeNewswire 4 days ago

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

GlobeNewswire November 8, 2024

Immatics Announces Pricing of $150 Million Public Offering

GlobeNewswire October 10, 2024

Immatics Announces Proposed $150 Million Public Offering

GlobeNewswire October 10, 2024

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

GlobeNewswire October 10, 2024

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

GlobeNewswire October 4, 2024

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

GlobeNewswire September 16, 2024

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

GlobeNewswire September 6, 2024

Immatics Announces Second Quarter 2024 Financial Results and Business Update

GlobeNewswire August 13, 2024
View More News ››

Opinion & Analysis (NDAQ:IMTX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IMTX)

Immatics Announces Updated Phase 1b Clinical Data on ACTengi

BREAKING NEWS: $IMTX Immatics Announces Updated Phase 1b Clinical Data on ACTengine&#xAE; IMA203 TCR-T Targeting PRAME in Melanoma...
whytestocks - October 10, 2024

Immatics Presents Clinical Proof-of-Concept Data from Ongoin

BREAKING NEWS: $IMTX Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific...
whytestocks - September 16, 2024
View more Bullboard ››

Lahontan Gold Corp.

Lahontan Gold Corp.

Lahontan Gold Corp. is a Canada-based mineral exploration company. The Company is engaged in the identification, acquisition, ...
View More »